Insilico Medicine nominated ISM9077 as a preclinical candidate for dry age-related macular degeneration, uveitis and dry eye disease.
The company claims ISM9077 is an AI-empowered potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential and that the molecule was designed, evaluated and optimized using the Chemistry42 generative AI platform.
Preclinical studies showed ISM9077 outperformed current therapies in dry AMD, uveitis and dry eye models while demonstrating a favorable safety margin, retinal exposure two to 5.5 times plasma levels, good permeability, favorable oral bioavailability and low-to-moderate clearance, supporting both oral and topical eye drop delivery.
The company also notes ISM9077 is its 32nd preclinical candidate nominated since 2021 and that Insilico typically reaches PCC nomination in about 12 to 18 months with 60 to 200 molecules synthesized and tested per program.
According to recent research, the global ocular diseases market exceeded USD 40 billion in 2025 and is projected to grow to USD 71.58 billion by 2034.
